gms | German Medical Science

58. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e. V. (DGNC)

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

26. bis 29.04.2007, Leipzig

In vitro labeling of glioma cells with Gadofluorine M enhances T1-visibility without affecting glioma cell growth or motility

Markierung von Glioblastomzellen mit Gadofluorine M in-vitro verbessert die native MR-Detektierbarkeit ohne Einschränkung der Migration und Proliferation

Meeting Abstract

  • corresponding author I. Nölte - Abteilung für Neuroradiologie, Universitätsklinikum Mannheim
  • S. Güngör - Abteilung für Neuroradiologie, Universitätsklinikum Mannheim
  • R. Erber - Abteilung für Neurochirurgie, Universitätsklinikum Mannheim
  • B. Misselwitz - Schering AG, Diagnostic Imaging Division, Berlin
  • C. Groden - Abteilung für Neuroradiologie, Universitätsklinikum Mannheim
  • M. A. Brockmann - Abteilung für Neuroradiologie, Universitätsklinikum Mannheim

Deutsche Gesellschaft für Neurochirurgie. 58. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e.V. (DGNC). Leipzig, 26.-29.04.2007. Düsseldorf: German Medical Science GMS Publishing House; 2007. DocP 083

The electronic version of this article is the complete one and can be found online at:

Published: April 11, 2007

© 2007 Nölte et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



Objective: Cell-tracking using MRI is most commonly done with iron-oxide particles. Gadofluorine M (GF) is a novel, non-iron-oxide contrast agent based on gadolinium with an amphiphilic character due to its perfluorinated side chain. In the underlying study we investigated whether the lipophilic properties of GF make labeling of malignant glioma cells in vitro feasible and enhance visualisation of glioma cells in MRI, which might be a helpful tool to track distribution patterns of tumor cells and tumor growth in vivo. Intracellular distribution of GF was analysed an proliferation and migration assays carried out to rule out adverse effects of GF on glioma cells.

Methods: U87-glioma cells were incubated with different concentrations of GF. Efficiency of the cell labeling process was analyzed by MRI. Fluorescence microscopic analyses and confocal laser scanning microscopy were used to demonstrate cellular uptake and to determine the intracellular distribution of Cy5-labeled GF. To ensure proper physiological function of GF-labeled cells, migration and proliferation assays were performed.

Results: We found that labeling of malignant glioma cells in vitro using Gadofluorine could easily be done without the need for special transfection agents or other additional means. Labeling of glioma cells with GF clearly enhanced visualisation of these cells in T1-weighted sequences, even after culturing cells in medium without GF. Significant loss of GF into the cell culture medium was ruled out by MRI. Confocal laser fluorescence microscopy revealed that Cy-5-labeled GF is localized in the perinuclear cytoplascmic region, but not within the nucleus nor bound to the cell membrane. Proliferation and migration of GF-labeled glioma cells was unchanged compared to unlabeled cells.

Conclusions: We conclude that Gadofluorine can easily be used to label glioma cells in vitro without significantly affecting glioma cell biology. Gadofluorine could represent an interesting alternative for cellular labelling in cases, where iron oxide particles are incorporated insufficiently by the target cells or if the vicinity to structures causing susceptibility artefacts prohibits the use of a signal-decreasing contrast agent.